Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

2022 ISR CRO Quality Bencdhmarking Survey

Discover what sponsors say about their experience working with Celerion.

Your early phase study is Celerion’s core business.

With over 50 years of experience and expertise in conducting early clinical research, we can be your full service clinical research organization (CRO) partner. Our clinics excel at conducting First-in-Human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, ADME, and renal and hepatic studies.

On site at our clinics, we also provide bioanalysis for small and large molecules (for pre-clinical and human studies). Our full service offering includes protocol design, data management, monitoring and PK/Statistical analysis. We also have extensive partner site relationships for your small patient studies. Let us share our experience as you plan your next clinical trial.

Download Our Complimentary CRO Quality Benchmarking Summary

Survey Results Are In!

Hear What Sponsors Are Saying About Working with Celerion.

Sponsors agree that Celerion is the “top choice provider they want to work with for Phase 1 Services.”

When it comes to meeting overall project timelines, Celerion “surpasses the competition.”

Client satisfaction drives customer loyalty and results show sponsors would recommend us and work with Celerion again.

Celerion Wins CRO Leadership Award

Celerion: Translating Science to Medicine

Evaluating Therapeutic Proteins in DDI Studies

Rifampin Drug–Drug–Interaction Studies

Onsite Pharmacy Compounding

Celerion Expands Early Phase Clinical Pharmacology Units